The presentation includes a brief corporate update from Leo Ehrlich, Chief Executive Officer, and a clinical overview by Dr. Arthur Bertolino, MD, PHD, MBA, President and Chief Medical Officer, with particular emphasis given to Brilacidin interim trial results in Inflammatory Bowel Disease and Oral Mucositis.

Click here or on the video below for the pre-recorded presentation.